With Parion Deal Done, Shire CEO Looks To Next Bright Ophthalmic Innovation
Shire's CEO Flemming Ornskov says he's focused on the specialist pharma's emerging ophthalmics division - and open to fresh innovative collaborations like that signed this week with Parion Sciences.
You may also be interested in...
Kala Pharmaceuticals is hoping to shake up the dry eye market with a NDA filing this year for its steroid eye drop KPI-121 0.25%.
Shire's CEO says he sees scientific and technological advances as an opportunity to become the leading rare disease company. Ornskov also talked about the firm's debt-reduction and M&A strategy going forward.
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.